Changing the Landscape

Millions of Americans suffer from central nervous system disorders. Tonix Pharmaceuticals is developing next-generation medicines to help.

Learn more

Latest News

Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)

• May 19, 2016 • 6:00 AM EDT

Read more

Management Team

Our experienced team has a strong track record of success in drug approvals and value creation.

View Management

Clinical Pipeline

Tonix's lead product candidate,TNX-102 SL, is being developed for the treatment of fibromyalgia. Tonix is also developing TNX-102 SL for the treatment of PTSD.

View Pipeline

About Tonix Pharmaceuticals

Tonix is developing next-generation medicines for common disorders of the central nervous system, including fibromyalgia and post-traumatic stress disorder. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden.

Learn more about tonix